onco exam 2: pharmacology

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/92

flashcard set

Earn XP

Description and Tags

lee, sivers

93 Terms

1
New cards

mab overview: what it does, parts

IgG that were designed to have a very specific target that is important for the survival and growth of cancer cells

  • bind to extracellular receptors or its natural ligand to prevent intracellular signaling

Parts:

  • Fab: fragment antigen-binding

  • Fc: fragment crystallizable


2
New cards

mab mechanisms (4)

  1. direct apoptosis

  2. Antibody-dependent cellular cytotoxicity

  3. Complement-dependent cytotoxicity

  4. anti VEGF antibiotics


3
New cards

Biosimilars

Drug that is highly similar, but not identical to a biologic drug due to differences in the manufacturing process

4
New cards

what is CD20 and what is it involved in(3)

A transmembrane calcium channel

Involved in B cell activation, proliferation, and maturation


5
New cards

what does anti- CD20 mabs do and what indications are they used for

Binds to CD20 on B cell surface and exerts (on B cells)

used for Lymphomas, chronic lymphocytic leukemia (CLL)

6
New cards

Anti-CD20 MAbs drugs

Rituximab

Obinutuzumab

Ofatumumab


7
New cards

EGFR Inhibitors drugs, moa, indication

Cetuximab and Panitumumab

moa: Block phosphorylation and activation of receptor-associated kinases

Colorectal cancer (EGFR-expressing without RAS mutations)


8
New cards

Cetuximab toxicity and BBW

Dermatologic toxicity/rash

Boxed warnings: Infusion reactions, cardiopulmonary arrest

9
New cards

Panitumumab BBW

BBW: Dermatologic toxicity/rash

10
New cards

Dermatologic Toxicity from Cetuximab prophylaxis and treatment

prophylaxis: general stuff like hydration, no sun, use alc free mostiruzers


treatment: topical steroids, topical antibiotics, systemic steroids, or tetracyclines

might need to hold dose based on severity*


11
New cards

HER-2 Inhibitors drugs, moa

drugs: Trastuzumab (Herceptin®); Pertuzumab (Perjeta®)

moa: Bind to extracellular domain of HER2 protein and inhibit downstream signaling, inducing apoptosis

12
New cards

HER-2 inhibitors tox and BBW

Boxed warning: Cardiotoxicity - LV dysfunction/heart failure (high risk esp. with anthracycline)

Boxed warning: Embryo-fetal toxicity

Boxed warning: pulmonary toxicity (except for pertuzumab) Infusion reaction (IV formulations only), hypersensitivity (all formulations


13
New cards

VEGF drugs, moas and indication

Bevacizumab binds to VEGF (ligand)

Ramucirumab binds to VEGFR-2 (receptor)

colorectal cancers

14
New cards

CTLA-4 inhibitors (immune checkpoint inhibitor)

Ipilimumab (Yervoy)

15
New cards

PD-1 inhibitors (immune checkpoint inhibitor)

Nivolumab (Opdivo)

Pembrolizumab (Keytruda)

16
New cards

PD-L1 inhibitors (immune checkpoint inhibitor)

Atezolizumab (Tecentriq)

Durvalumab (Imfinzi)

17
New cards

Antibody Drug Conjugates moa

MAbs are linked with a cytotoxic payload to increase cytotoxicity of mAbs, while maintaining specificity for a tumor cell target

18
New cards

Ado-trastuzumab emtansine BBW and cytotoxic payload

cardiotoxicity

cytotoxic payload: DM1 (microtubule inhibitor)

19
New cards

Fam-Trastuzumab Deruxtecan (Enhertu®) BBW and cytotoxic payload

interstitial lung disease

cytotoxic payload: DXd (topoisomerase I inhibitor)


20
New cards

Inotuzumab ozogamicin BBW and cytotoxic payload

Hepatotoxicity (risk of veno-occlusive disease), increased risk of non-relapse mortality post-stem cell transplant

cytotoxic payload: Calicheamicin derivative (antitumor antibiotic)


21
New cards

Gemtuzumab ozogamicin BBW and cytotoxic payload

Boxed warning: Hepatotoxicity (risk of veno-occlusive disease)

cytotoxic payload: Calicheamicin derivative (antitumor antibiotic)


22
New cards

supportive care for Gemtuzumab ozogamicin and Inotuzumab ozogamicin

Premedicate with corticosteroid, antipyretic, and antihistamine

23
New cards

Polatuzumab vedotin cytotoxic payload and supportive care

cytotoxic payload:

Premed with antihistamine, antipyretic

24
New cards

Brentuximab vedotin and Polatuzumab vedotin cytotoxic payload

Monomethyl auristatin E (MMAE)

25
New cards

Bispecific T-cell Engager (BiTE) moa and indications

Antibodies that target one tumor antigen and one immune-related molecule (CD3 on T cells)

used for B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, multiple myeloma

26
New cards

Blinatumomab binds where and to what; and what class?

Binds to CD19 on B-cells and CD3 on T-cells

Anti-CD19 BiTE

27
New cards

Blinatumomab BBW and supportive care

Cytokine release syndrome, neurotoxicity

give corticosteroids before each dose and hospitalization is recommended for atleast first 2 doses

28
New cards

what does dysregulation of RTKs lead to?

cancer cell survival

29
New cards

Mechanisms of RTKs in cancer

  1. gain of function mutations→ persistant activation

  2. amplification/overexpression of receptors

  3. chromosomal rearrangements


30
New cards

what type of drugs are Tyrosine Kinase inhibitors usually?

small molecule drugs which involve mutations within RTKs

31
New cards

Targets of TKIs in hematological cancers

BCR-ABL

FLT3

32
New cards

BCR-ABL inhibitor mechanism and target

inhibit BCR-ABL tyrosine kinase, blocking cancer cell proliferation and inducing apoptosis

target is the BCR-ABL fusion oncoprotein

33
New cards

Resistance to BCR-ABL inhibtors (primary and secondary)

primary: not as common; defined as no remission in 3-18 months after initiation


secondary: T315I mutation

34
New cards

if a pt has T315I mutation, which drugs can work?

ponatinib and asciminib

35
New cards

Imatinib class and indication

1st gen BCR-ABL inhibitor (TKIs)

for Ph+ CML, Ph+ ALL, gastrointestinal stromal tumors (GIST)

36
New cards

Imatinib couseling pt and toxcity

take with food

tox: fluid retention (periorbital edema) fluid around eyes

37
New cards

Dasatinib class and indication

2nd generation BCR-ABL inhibitor

indication: Ph+ CML, Ph+ ALL

38
New cards

Dasatinib DDI and tox

Do not administer PPIs and H2RAs concomitantly with dasatinib

tox: fluid retention (pleural or pericardial effusions), pulmonary arterial hypertension (PAH),

39
New cards

Nilotinib class and indication

2nd generation BCR-ABL inhibitor

Ph+ CML

40
New cards

Nilotinib DDI, couseling pt, tox, BBW

DDI: H2RAs and PPIs

take on empty stomach

Toxicities: metabolic syndrome

BBW: QTc interval prolongation and sudden death

41
New cards

Bosutinib class and indication

2nd generation BCR-ABL inhibitor

Indications: Ph+ CML

42
New cards

Bosutinib couseling pt, DDI and tox

DDI: H2RAs and PPIs

take with food

tox: diarrhea, N/V (moderate/high emetogenic potential)

43
New cards

Ponatinib class and indication

3rd generation BCR-ABL inhibitor

for Ph+ CML, Ph+ ALL

44
New cards

Ponatinib couseling and BBW

take with food

BBW: arterial occlusive events, VTE

45
New cards

Asciminb class, moa, and indication

STAMP Inhibitor

  • allosteric inhibiton by targeting the ABL myristoyl pocket)

indication: Ph+ CML (new or if it came back diagnosis)


46
New cards

Asciminb couseling pt and tox

take without food

tox: pancreatitis, hypertension

47
New cards

FLT3 mutations, types, and which inhibitors work for those types

FLT3 mutations are activating mutations that promote leukemic cancer cell survival and proliferation

1) Internal tandem duplication (ITD)

  • Type 2 inhibitors only

2) Tyrosine kinase domain (TKD)

  • type 1 and type 2 inhibitors


48
New cards

Type 1 and 2 inhibitors diff how

Type 1→ bind only in active conformation

Type 2→ bind only in inactive conformation

49
New cards

Midostaurin class and indication

type 1 FLT3 inhibitor

newly diagnosed FLT3-positive AML in combo w/standard chemotherapy induction & consolidation

50
New cards

Midostaurin tox

gastrointestinal (N/V, high-moderately emetogenic), QTc interval prolongation

51
New cards

Gilteritinib class and indication

type 1 FLT3 Inhibitor

relapsed/refractory FLT3-positive AML

52
New cards

Gilteritinib tox

Differentiation syndrome (BBW), QTc interval prolongation, pancreatitis, posterior reversible encephalopathy syndrome (PRES)

53
New cards

Quizartinib class and indication

type 2 FLT3 inhibitor

newly diagnosed FLT3 internal tandem duplication (ITD) positive AML in combo w/standard chemotherapy induction, consolidation, and maintenance

54
New cards

Quizartinib tox, BBW, monior and imp

QTc interval prolongation, Torsades de points and cardiac arrest (BBW),

  • so monitor w ECG

REMS program à BBW for QTc interval prolongation, Torsade's de Pointes, and cardiac arrest


55
New cards

EGFR inhibitor moa and how

Gain-of-function mutations from exon 19 or exon 21 L858R

56
New cards

EGFR TKIs vs mabs

TKIs: bind to intracellular kinase domain of the EGFR (ErbB-1) and block the binding of ATP,


mabs: inhibit the extracellular ligand binding-site of EGFR

57
New cards

Resistance to EGFR inhibitors and which is an exception

T790M mutation→ resistance to all commercially available EGFR TKIs except osimertinib

58
New cards

EGFR inhibitors tox

Derm related bc increased chemokines and inflammation

NOT ACNE

59
New cards

Erlotinib class, indication and DDI

EGFR inhibitor for pancreatic + NSCLC

DDI: PPIs, separate from H2RAs

60
New cards

Lazertinib class, imp point, tox

EGFR inhibitor for NSCLC in combo w/ amivantamab NEVER alone

tox: VTE: PPX anti- coagulation for 1st 4 months)

61
New cards

ALK inhibitors moa

Formation of EML4-ALK fusion oncoprotein makes the ALK, so inhibiting ALK→ induces apoptosis and blocking cancer cell proliferation

62
New cards

ALK inhibitors indication and one med with 2 indications

Metastatic ALK NSCLC

Crizotinib→ Metastatic ALK or ROS1 (+) NSCLC

63
New cards

HER2 inhibitors moa

proto-oncogene overexpressed; HER2 TKIs bind to the intracellular tyrosine kinase domain of HER2 (ErbB-2),

64
New cards

Lapatinib class and indication

HER2 inhibitor

metastatic HER2 positive breast cancer

65
New cards

Lapatinib tox and BBW

tox: cardiac (decreases in LVEF), diarrhea,

BBW: hepatotoxicity

66
New cards

Neratinib class and indication

HER2 inhibitor

extended adjuvant therapy in high risk, HER2 positive breast cancer

67
New cards

Neratinib tox and supportive care

tox: diarrhea,

supportive care: Antidiarrheal prophylaxis

68
New cards

BCL2 inhibitor moa

binds directly to the BCL2 protein→ leading to apoptosis

69
New cards

Venetoclax class, indication

BCL2 inhibitor

acute myeloid leukemia (AML) in adults 75 years or older or with comorbidities that prevent intensive chemo,

70
New cards

Venetoclax dosing, tox

concomitant use with moderate or strong CYP3A4 inhibitor

ramp up dosing

tox→ tumor lysis syndrome, bone marrow suppression,

71
New cards

Idelalisib class and indication

Selective PI3Kδ(delta) Inhibitor

Chronic lymphocytic leukemia (CLL) w/rituximab

72
New cards

Idelalisib bbw

Hepatotoxicity, diarrhea/colitis, pneumonitis, infections and intestinal perforation

VERY TOXiIC

73
New cards

Alpelisib class and indication

Selective PI3K⍺ inhibitor

PIK3CA-mutated, HR (+), HER2 (-) metastatic breast cancer

74
New cards

Alpelisib tox

hyperglycemia

think a1c bc PI3Ka

75
New cards

Inavolisib class and indication

Selective PI3K⍺ inhibitor

PIK3CA-mutated, HR (+), HER2 (-) metastatic breast cancer in combo with fulvestrant + palbociclib

76
New cards

Inavolisib tox

Stomatitis, Hyperglycemia

77
New cards

CDK 4/6 inhibitors drugs

Ribociclib, Palbociclib, Abemaciclib

78
New cards

CDK 4/6 inhibitors inidications

HR-positive, HER2- negative, advanced or metastatic breast cancer

79
New cards

PARP inhibitors moa

bind to PARP and prevent the repair of single-strand DNA breaks, leading to double stranded breaks

80
New cards

PARP inhibitors drugs, indications, and tox

Olaparib and Talazoparib

  • both for BRAC mutated cancers


taalazoparib→ needs to be metastized breast cancer

olarparib→ can use against any

tox→ secondary malignancies

81
New cards

BRAF/MEK inhibitors drugs and mutation

BRAF→ Dabrafenib; Encorafenib, Vemurafenib

MEK→ Trametinib; Binimetinib, Cobimetinib

need BRAF V600E/K mutations


82
New cards

BRAF/MEK inhibitors specifc indications

Vemurafenib/Cobimetinib → mutated melanoma only

Encorafenib/ Binimetinib→ mutated melanoma, metastatic NSCLC

Dabrafenib/ Trametinib→ mutated melanoma, non- small cell lung cancer, advanced solid tumors

83
New cards

BRAF/MEK tox

Dermatologic (rash, skin cancers) - DLT

Pyrexia

84
New cards

IDH mutation

normal: isocitrate to ⍺-ketoglutarate

Mutations in IDH enzymes convert ⍺-KG to 2-hydroxyglutarate (2-HG)

85
New cards

IDH inhibitors drugs, indications, tox

Ivosidenib→ IDH1 mutated AML

Enasidenib→ IDH2 mutated

tox for both→ differentiation syndrome

86
New cards
87
New cards
88
New cards
89
New cards
90
New cards
91
New cards
92
New cards
93
New cards